Comparative Pharmacology
Head-to-head clinical analysis: CARDIOTEC versus DRAXIMAGE DTPA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CARDIOTEC versus DRAXIMAGE DTPA.
CARDIOTEC vs DRAXIMAGE DTPA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
CARDIOTEC is a technetium-99m labeled tracer that binds to viable myocardial cells. Its uptake is dependent on mitochondrial membrane potential and reflects myocardial perfusion and viability. The exact mechanism involves passive diffusion across cell membranes and retention within mitochondria via interaction with the mitochondrial complex I (NADH dehydrogenase).
DRAXIMAGE DTPA (technetium Tc-99m pentetate) is a radiopharmaceutical that, after intravenous injection, distributes in the extracellular space and is cleared by glomerular filtration. It allows imaging of renal function and structure by emitting gamma radiation detectable by a gamma camera.
220-260 MBq (6-7 mCi) intravenously as a single dose for planar or SPECT imaging.
Diagnostic imaging: 3-5 mCi (111-185 MBq) IV for renal studies; 10-20 mCi (370-740 MBq) IV for lung perfusion imaging.
None Documented
None Documented
Terminal elimination half-life is 6-8 hours; clinically, steady-state achieved in 24-32 hours
Terminal elimination half-life is approximately 1.6 hours (range 1.2-2.0 hours) in patients with normal renal function; prolonged in renal impairment (up to 50 hours in severe cases).
Renal: 70% as unchanged drug; biliary/fecal: 25% as metabolites; 5% other
Renal: 95% within 24 hours via glomerular filtration; biliary/fecal: <5%.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical